NeOnc Technologies Holdings Inc
NTHI9.770USD
+0.530+5.74%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
190.26MMarket Cap
LossP/E TTM
More Details of NeOnc Technologies Holdings Inc Company
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
NeOnc Technologies Holdings Inc Info
Ticker SymbolNTHI
Company nameNeOnc Technologies Holdings Inc
IPO dateMar 26, 2025
CEOHeshmatpour (Amir F)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endMar 26
Address23975 Park Sorrento
CityCALABASAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91302
Phone13106637831
Websitehttps://neonc.com/
Ticker SymbolNTHI
IPO dateMar 26, 2025
CEOHeshmatpour (Amir F)
Company Executives of NeOnc Technologies Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Bader Almonawer
Mr. Bader Almonawer
Lead Independent Director
Lead Independent Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Dr. Thomas C. Chen, M.D., Ph.D.
Dr. Thomas C. Chen, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Director
Chief Medical Officer, Chief Scientific Officer, Director
--
--
Mr. Keithly A. Garnett
Mr. Keithly A. Garnett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amir F. Heshmatpour
Mr. Amir F. Heshmatpour
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Victoria Medvec, Ph.D.
Dr. Victoria Medvec, Ph.D.
Independent Director
Independent Director
--
--
Hon. Jim Delshad
Hon. Jim Delshad
Independent Director
Independent Director
--
--
Ms. Laurie Berman
Ms. Laurie Berman
Investor Relations
Investor Relations
--
--
Mr. Josh Neman
Mr. Josh Neman
Chief Clinical Officer
Chief Clinical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Bader Almonawer
Mr. Bader Almonawer
Lead Independent Director
Lead Independent Director
50.16K
--
Dr. Steven L. Giannotta, M.D.
Dr. Steven L. Giannotta, M.D.
Independent Director
Independent Director
50.16K
--
Dr. Thomas C. Chen, M.D., Ph.D.
Dr. Thomas C. Chen, M.D., Ph.D.
Chief Medical Officer, Chief Scientific Officer, Director
Chief Medical Officer, Chief Scientific Officer, Director
--
--
Mr. Keithly A. Garnett
Mr. Keithly A. Garnett
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Amir F. Heshmatpour
Mr. Amir F. Heshmatpour
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Victoria Medvec, Ph.D.
Dr. Victoria Medvec, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 17
Updated: Wed, Dec 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Chen (Thomas C.)
22.52%
AFH Holding & Advisory, L.L.C.
19.07%
Heshmatpour (Amir Farrokh)
18.18%
Chiang (Ming-Fu Alan)
7.22%
HighPoint Advisor Group, LLC
5.88%
Other
27.12%
Shareholders
Shareholders
Proportion
Chen (Thomas C.)
22.52%
AFH Holding & Advisory, L.L.C.
19.07%
Heshmatpour (Amir Farrokh)
18.18%
Chiang (Ming-Fu Alan)
7.22%
HighPoint Advisor Group, LLC
5.88%
Other
27.12%
Shareholder Types
Shareholders
Proportion
Individual Investor
50.16%
Corporation
24.33%
Investment Advisor
8.14%
Research Firm
1.26%
Investment Advisor/Hedge Fund
0.93%
Other
15.18%
Institutional Shareholding
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
23
1.79M
3.13%
--
2025Q4
23
2.03M
10.43%
+550.00K
2025Q3
17
1.61M
8.43%
+1.29M
2025Q2
18
10.40M
54.67%
-137.09K
2025Q1
15
8.72M
46.52%
+8.72M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Chen (Thomas C.)
4.39M
22.52%
+1.54M
+54.01%
Dec 12, 2025
AFH Holding & Advisory, L.L.C.
3.71M
19.07%
--
--
Dec 12, 2025
Heshmatpour (Amir Farrokh)
3.54M
18.18%
+1.19M
+50.60%
Dec 12, 2025
Chiang (Ming-Fu Alan)
1.41M
7.22%
+967.76K
+220.64%
Dec 12, 2025
HighPoint Advisor Group, LLC
950.23K
4.88%
+769.16K
+424.79%
Sep 30, 2025
HCWG LLC
1.02M
5.26%
--
--
Dec 12, 2025
BofA Global Research (US)
226.49K
1.16%
+2.21K
+0.98%
Sep 30, 2025
The Vanguard Group, Inc.
140.91K
0.72%
+140.91K
--
Sep 30, 2025
Garnett (Keithly)
161.35K
0.83%
+160.45K
+17828.00%
Dec 12, 2025
BlackRock Institutional Trust Company, N.A.
148.51K
0.76%
+143.40K
+2807.44%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
